← Back to screener

ADMA BIOLOGICS, INC. ADMA

Rank #2214 · Nasdaq · $2.6B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
29.0
P/E
-93.6
P/B
17.40
ROE
-18.6%
Op. Margin
8.4%
Debt Ratio
92%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -93.6x, P/B 17.40x. Ranks in the top 78% of the universe.

Profitability ★★☆☆☆
Weak

ROE -18.6%. Ranks in the top 64% of the universe.

Safety ★★★☆☆
Good

Debt ratio 92%. Ranks in the top 37% of the universe.

Growth ★★★★★
Excellent

Revenue growth of 67.6% year over year. Ranks in the top 6% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2012$0.0B$-0.0B$-0.0B$-0.0B-607.5-65
2013$0.0B$-0.0B$-0.0B$0.0B-707.465
2014$0.0B$-0.0B$-0.0B$0.0B-490.4110
2015$0.0B$-0.0B$-0.0B$0.0B-270.897
2016$0.0B$-0.0B$-0.0B$0.0B-216.1381
2017$0.0B$-0.0B$-0.0B$0.0B-162.63428
2018$0.0B$-0.0B$-0.0B$-0.0B-172.7-1519
2019$0.0B$-0.1B$-0.1B$0.0B-354.9171
2020$0.0B$-0.0B$-0.0B$0.0B-141.1510
2021$0.0B$-0.1B$-0.1B$0.0B-153.8456
2022$0.1B$-0.1B$-0.1B$0.1B-72.1153
2023$0.1B$-0.1B$-0.1B$0.1B-72.1223
2024$0.2B$-0.0B$-0.1B$0.1B-25.5137
2025$0.3B$0.0B$-0.0B$0.2B8.492

← See the full screener